Results 181 to 190 of about 2,071,373 (281)

A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour‐targeting function

British Journal of Pharmacology, Volume 183, Issue 22, Page 6685-6703, November 2026.
Abstract Background and Purpose Site‐specific antibody modification is a useful chemical strategy to elaborate antibody therapeutic function. Conventional lysine‐ or cysteine‐based conjugation methods generate heterogeneous products, while protein engineering approaches are resource‐intensive.
Karolina Krygier, Sandra Szu‐Wei Hwang, Anthony F. Rullo   +2 more
wiley   +1 more source

Management of submacular hemorrhage secondary to age-related macular degeneration with vitrectomy and subretinal tissue plasminogen activator injection: Outcomes and prognostic factors. [PDF]

SAGE Open Med
Li MM, Zhang H, Cen ZM, Su DW.
europepmc   +1 more source

SERPINE1 Alternative Polyadenylation Influences Gastric Cancer Prognosis via N6‐Methyladenosine Modification

Cancer Science, Volume 117, Issue 11, Page 3132-3145, November 2026.
Multi‐omics integration of the transcriptomic APA landscape and m6A modifications identifies key prognostic genes. Their biological functions and molecular mechanisms in promoting tumor progression are comprehensively validated through in vitro assays. ABSTRACT Alternative polyadenylation (APA) and N6‐methyladenosine (m6A) methylation are critical post‐
Zhuoyi Wu, Ruyun Xu, Ju Fang, Bing Liu, Cao Zhang, Shangxin Zhang, Jing Ni   +6 more
wiley   +1 more source

Rhenium‐Based β‐Galactosidase Probe Allows Senescence Profiling by Mass Cytometry

Angewandte Chemie, Volume 138, Issue 42, 12 October 2026.
Senescence‐associated β‐galactosidase (SA‐β‐Gal) activity is a widely accepted biomarker of cellular senescence, yet its integration with other senescence markers has been limited by available detection methods. Here, we introduce ReGal, a mass cytometry‐compatible SA‐β‐Gal activity probe that can be multiplexed with established markers of senescence ...
Adam Tam, Kris Elbein, Aleida G. Gonzalez, Edgar A. Arriaga, Mark Nitz   +4 more
wiley   +2 more sources

Successful Intraluminal Administration of Tissue Plasminogen Activator for Life-Threatening Obstructive Hematoma in Extremely Preterm Infants. [PDF]

J Korean Med Sci
Kim SH, Ahn SY, Kim H, Hwang J, Yang M, Sung SI, Chang YS.   +6 more
europepmc   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

European Journal of Haematology, Volume 117, Issue 5, Page 1369-1377, November 2026.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Kyung‐Sang Yu, In‐Jin Jang, Hyoung Jin Kang   +6 more
wiley   +1 more source

Free Flap Salvage Using Extracorporeal Tissue Plasminogen Activator Administration: A Comparative Study. [PDF]

Plast Reconstr Surg Glob Open
Johansen A, Halle M, Rittri S.
europepmc   +1 more source

Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors. [PDF]

Am Heart J Plus
Jalili J, Vaseghi S, Asvadi T, Baastani Khajeh M.   +3 more
europepmc   +1 more source

Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

Journal of Internal Medicine, Volume 300, Issue 5, Page 590-609, November 2026.
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund, Johanna Melin, Anju E. Joham, Terhi T. Piltonen, D. Aled Rees, Helena J. Teede   +5 more
wiley   +1 more source

Tissue Plasminogen Activator to Resolve Elevated Purge System Pressure in a Catheter-Based Ventricular Assist Device. [PDF]

JACC Case Rep
Khattak S, Shamkhani W, Maqableh GM, Al-Shatanawi A, Khan SQ.   +4 more
europepmc   +1 more source